The strategy to initiate SGLT2 inhibitors in patients with type 2 diabetes according to HbA1c ≥ 7.5% would involve treating 2809 (78.3%) of the population in order to prevent 33.0 (95% CI 18.8 to 43.3) kidney events. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.